ENCORE - A Randomized Double-Blind Placebo-Controlled Active Comparator Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Myco

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Mycobacterium Avium Complex
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Current diagnosis of MAC lung infection
    2. Positive sputum culture for MAC within 6 months prior to Screening
    3. Positive sputum culture for MAC at Screening
    4. A high-resolution chest computed tomography (CT) scan o

You may not be eligible for this study if the following are true:

    1. Diagnosis of cystic fibrosis (CF)
    2. History of 3 or more prior MAC lung infections
    3. Received any mycobacterial antibiotic treatment for current MAC lung infection
    4. Refractory MAC lung infection
    5. Relapse


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.